Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-10-04-Speech-4-117"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2001-10-04"^^xsd:date2
dcterms:Is Part Of	lp_eu:VOTE2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20011004.3.4-117"2
lpv:hasSubsequent	lp_eu:2001-10-04-Speech-4-1182
lpv:speaker	lp:Erik Meijer2
lpv:spokenAs	unknown; Socialistische Partij (1999-07-20--2004-07-19)3 member_of_the_bureau; EUL/NGL (1999-10-13--2004-07-19)3 member; Committee on Regional Policy, Transport and Tourism (1999-07-21--2002-01-14)3 member; Delegation to the EU-Slovak Republic Joint Parliamentary Committee (1999-09-29--2002-01-14)3 substitute; Temporary committee on human genetics and other new technologies in modern medicine (2000-12-13--2001-11-29)3 substitute; Delegation to the EU-Czech Republic Joint Parliamentary Committee (2000-11-09--2002-01-14)3 substitute; Committee on the Environment, Public Health and Consumer Policy (1999-07-21--2002-01-14)3
lpv:translated text	". In questions to the European Commission, I have already on a number of occasions strongly recommended measures to ensure that medicines to combat prevalent fatal diseases are available to inhabitants of the Third World. Remedies against tropical diseases are often available to foreign tourists from rich countries, but not to the large majority of the local population. Existing medicines, which have worked effectively for many years, are even being withdrawn from the market. The reason for this is the lack of spending power in those countries to buy these medicines. If we see medicines as mere commodities, protected by patent rights which ensure that the cost of earlier development expenditure is forever passed on, there will be no medicines available to poor countries and certainly not to their poorest inhabitants. Such medicines often cost more than the annual income of people living there. The proposals by Mr Khanbhai for international recognition by the EU of the right of developing countries to produce generic treatments for epidemic diseases without having to pay the costs of intellectual property rights, as well as the stimulation of production of treatments for diseases caused by poverty and the periodical review of the TRIPs agreement are essential to reach a solution."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph